Renaud Bonnet

Practice Leader Private Equity

巴黎 + 33.1.56.59.39.14

聯絡

*Share

Renaud Bonnet is co-leader of Private Equity for the Firm's Corporate Practice. His practice areas include venture capital, private equity, M&A, and capital markets. He represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.

Renaud's recent experience includes representations of technology and life sciences companies Adocia, Ansys, Cellectis, Criteo, Deezer, Devialet, EcoVadis, HRA Pharma, Ivalua, 360Learning, ManoMano, Nanobiotix, Planisware, Prodways, Sigfox, Talend, and Voltalia. His recent investor-side representations include: Abingworth, Alven, Bain Capital Ventures, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Institut Pasteur, Sanofi, Seventure, Sofinnova, and Temasek.

Transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, Nanobiotix, and Talend on Nasdaq; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and EcoVadis.

Renaud was a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF) from 2017 to 2019.

執業經驗

  • Consortium of investors leads Melvan's €25 million fundraisingJones Day advised a consortium of investors led by Bpifrance, IDIA Capital Investissement, a pool of other investors from the Crédit Agricole group, and OCCTE, in connection with the €25 million financing of Melvan, a French producer and developer of multi-technology renewable energies.
  • Oscar sells Olféo to EkinopsJones Day advised the management and shareholders of Oscar (Olféo group), a French provider of Secure Service Edge cybersecurity software and web security gateways, in connection with the sale of the company to Ekinops, a French supplier of open and interoperable telecommunications solutions.
  • Bioptimus receives €41 million financingJones Day advised Bioptimus, the pioneering AI foundation model company, in its €41 million financing led by Cathay Innovation with participation from Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf.
  • CVE Biogaz raises €70 millionJones Day advised CVE Biogaz, a major player in organic matter recovery and methanization in France, in raising €70 million from BNP Paribas Asset Management, accelerating its development and strengthening its position in the European methanization market.
  • bsport receives €30 million investmentJones Day advised bsport in its €30 million Series B financing.
  • Kyotherm raises €300 millionJones Day advised Kyotherm, a co-developer and financer of renewable heat and energy efficiency projects, in connection with its €300 million financing led by InfraVia Capital Partners and existing investor, Andera Partners.
  • Creadev and Banque des Territoires invest in ipso santéJones Day advised Creadev SAS and Banque des Territoires in connection with an investment in ipso santé, a network of medical practices.
  • Revaia and Bpifrance lead €27 million Series B financing of FASSTJones Day advised Revaia and Bpifrance in connection with the €27 million Series B financing of FASST, a major player in the digitalization of insurance product distribution to insurers, mutuals and brokers across Europe.
  • Agicap raises capital in €45 million Series C financingJones Day advised Agicap, the all-in-one Treasury management platform, in connection with its €45 million Series C financing led by AVP.
  • Elaia Partners participates in £35 million Series B financing of DocclaJones Day advised Elaia Partners in connection with its participation in the £35 million Series B financing of Doccla, the leading provider of virtual ward and remote patient monitoring services, particularly targeting France and the DACH region for expansion while also positioning the company for potential growth in other international markets beyond Europe.
  • Zebra Impact Ventures and BPI Green Tech Investment lead $29 million Series B financing of Micropep TechnologiesJones Day represented Zebra Impact Ventures and BPI Green Tech Investment as lead investors in the $29 million Series B financing of Micropep Technologies, the global leader in micropeptide technology.
  • BNP Paribas participates in $640 million Series B financing of Mistral AIJones Day advised BNP Paribas in the $640 million Series B financing of Mistral AI, an AI-powered solutions company, including data entry systems and large language models.
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZenecaJones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million.
  • Hi Inov participates in €6 million financing of ANOZR WAYJones Day advised Hi Inov in connection with the €6 million financing of ANOZR WAY, a leading pioneer in cyber protection for executives and companies, along with lead investor Clearwater International and existing investors.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • VIALINK sold to SignaturitJones Day advised VIALINK in the sale of the company to PSG-backed Signaturit.
  • TiLT Capital Partners leads €46 million financing of EODevJones Day advised TiLT Capital Partners SAS in leading the €46 million financing of EODev, along with Supernova Invest, CapHorn, Pulse (CMA-CGM), and the existing shareholders of EODev, to strengthen its leading position in the hydrogen fuel cell power generators market by financing its investment program, the expansion of its product range, and the acceleration of its commercial development.
  • Contentsquare acquires HeapJones Day acted as French counsel to Contentsquare in the acquisition of Heap, a leading U.S. product analytics platform.
  • Arverne Group combines with Transition to publicly list on Euronext Paris the future French leader in geothermal and low-carbon lithium to drive energy transitionJones Day advised Arverne Group SAS, a French company ("Arverne"), in its business combination with Euronext listed Transition SA to create the future French leader in geothermal and low-carbon lithium production.
  • Sofinnova and NVentures co-lead $55.4 million financing of Moon SurgicalJones Day advised Sofinnova Partners (through Sofinnova Capital Strategy) and NVentures (NVIDIA's venture capital arm) as lead investors in connection with the $55.4 million financing of Moon Surgical, a French-American pioneer in collaborative robotics.
    •

    March 2023 White Paper

    2022 Annual M&A/PE Review and 2023 Forecast

    January 2022 White Paper

    2021 Transactional Year in Review and 2022 Forecast

    January 2022 White Paper

    FDI Regimes Continue to Expand and Increase Scrutiny of Transactions Worldwide

    February 2021 White Paper

    2020 Transactions Year in Review

    June 2016 Alert

    Brexit: United Kingdom Votes to Leave the EU

    September 18-20, 2023 Speaking Engagements

    Jones Day lawyers to attend IPEM 2023

    • 29 janvier 2014
      Le private equity en 2014 : tendances et opportunités
    • 29 janvier 2013
      Le Private Equity : où en sommes-nous ?
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 5 avril 2011
      Atelier « Fusions & Acquisitions » de France Biotech - Le point de vue de l'avocat, intervention de Renaud Bonnet
    • 17 juin 2009
      Introductions en bourse : la mission de l’avocat conseil et la problématique règlementaire, Conférence “Penser à votre introduction en bourse : osé ... mais peut-être astucieux ! ” organisée par la Société Générale
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    • 18 mai 2006
      Petit déjeuner thématique "Stock options, BCE, actions gratuites"
    • 14 mars 2006
      Cours à l'ESSEC, "Mécanisme d'incitation des managers"

    *Before sending, please note:

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.